Clinical Trials

BreastGenitourinaryThoracic

261 enrolled 12 charts

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasm Metastasis, Pain, Prostatic Neoplasms

NCT03336983 2024-08-01

BonEnza

126 enrolled

Phase 2/3 Active not recruiting

Prostatic Neoplasms

NCT00268476 2023-04-18

STAMPEDE

11,992 enrolled

Prostatic Neoplasms

NCT00058188 2020-12-08

Zolendronate for the Prevention of Bone Loss in Men w/ Prostate CA on Long-Term Androgen Deprivation

53 enrolled

Osteoporosis, Prostatic Neoplasms

NCT02721433 2020-12-02

REaCT-BTA

263 enrolled

BreastGenitourinary

Breast Neoplasms, Neoplasm Metastasis, Prostatic Neoplasms

NCT00079001 2020-05-12

Zoledronate in Preventing Skeletal (Bone)-Related Events in Men Who Are Receiving Androgen Deprivation Therapy For Prostate Cancer and Bone Metastases

645 enrolled 13 charts

Neoplasm Metastasis, Prostatic Neoplasms

NCT00582556 2019-11-26

Zometa on Bone Mineral Density in Prostate Cancer Patients Undergoing Androgen Ablation Therapy

44 enrolled 8 charts

Prostatic Neoplasms

NCT01006395 2019-07-05

Prevention of Micro-architectural Bone Decay in Males With Non-metastatic Prostate Cancer Receiving Androgen Deprivation Therapy (ADT)

Phase 2/3 Completed

64 enrolled

Insulin Resistance, Prostatic Neoplasms

NCT01205646 2019-04-12

PET Scanning to Evaluate Zoledronate Efficacy in Metastatic Prostate Cancer

11 enrolled 7 charts

Neoplasm Metastasis, Prostatic Neoplasms

NCT00869206 2018-11-07

Zoledronic Acid in Treating Patients With Metastatic Breast Cancer, Metastatic Prostate Cancer, or Multiple Myeloma With Bone Involvement

BreastGenitourinaryPlasma cell

1,822 enrolled 19 charts

Breast Neoplasms, Multiple Myeloma, Pain, Prostatic Neoplasms

NCT00329797 2017-11-29

Zoledronate in Preventing Osteoporosis and Bone Fractures in Patients With Locally Advanced Nonmetastatic Prostate Cancer Undergoing Radiation Therapy and Hormone Therapy

109 enrolled 8 charts

Osteoporosis, Prostatic Neoplasms

NCT00193856 2017-10-12

RADAR Trial - Randomised Androgen Deprivation and Radiotherapy

1,071 enrolled

Prostatic Neoplasms

NCT00063609 2017-09-13

The Effect of Zoledronic Acid on Bone Loss in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy

200 enrolled

Bone Diseases, Metabolic, Osteoporosis, Prostatic Neoplasms

NCT00375648 2017-06-02

TRAPEZE

61 enrolled

Neoplasms, Pain, Prostatic Neoplasms

NCT00219271 2017-05-31

Effect Of Zoledronic Acid On Circulating And Bone Marrow-Residing Prostate Cancer Cells In Patients With Clinically Localized Prostate Cancer

60 enrolled

Prostatic Neoplasms

NCT00172055 2017-03-06

Study to Assess Efficacy and Safety of Zoledronic Acid and the Value of Markers of Bone Resorption in the Prediction of Bone Metastases and Cancer Treatment-induced Bone Loss (CTIBL) in Patients With Prostate Cancer on Hormone Therapy

218 enrolled

Osteoporosis, Prostatic Neoplasms

NCT00434447 2017-02-27

Long Term Efficacy and Safety of Zoledronic Acid Treatment in Patients With Bone Metastases

BreastGenitourinaryPlasma cellSarcoma

73 enrolled

Bone Neoplasms, Breast Neoplasms, Multiple Myeloma, Prostatic Neoplasms, Renal Insufficiency

NCT00171639 2017-02-23

The Use of Zoledronic Acid in Men on Androgen Deprivation Therapy for Prostate Cancer With Preexisting Osteoporosis

28 enrolled

Prostatic Neoplasms

NCT00237146 2017-02-23

Study to Evaluate Zoledronic Acid on Quality of Life and Skeletal-related Events as Adjuvant Treatment in Patients With Hormone-naïve Prostate Cancer and Bone Metastasis Who Have Undergone Orchiectomy

38 enrolled

Prostatic Neoplasms

NCT00242554 2017-02-23

Open-label Phase IV Clinical Trial to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastases

150 enrolled

Prostatic Neoplasms

NCT00434317 2017-02-23

Assessment of Pain and Quality of Life in Breast and Prostate Cancer Patients With Bone Metastases

80 enrolled

BreastGenitourinary

Breast Neoplasms, Neoplasm Metastasis, Neoplasms, Pain, Prostatic Neoplasms

NCT00334139 2017-02-07

Effect of Zoledronic Acid on Bone Metabolism in Patients With Bone Metastasis and Prostate or Breast Cancer

411 enrolled

BreastGenitourinary

Breast Neoplasms, Prostatic Neoplasms

NCT00391690 2016-11-18

Evaluation of Bone Markers as Diagnostic Tools for Early Detection of Bone Metastases in Patients With High Risk Prostate Cancer

99 enrolled

Prostatic Neoplasms

NCT00081159 2016-11-10

Hormone Ablation Therapy, Doxorubicin, and Zoledronate With or Without Strontium 89 in Treating Patients With Androgen-Dependent Prostate Cancer and Bone Metastases

80 enrolled 6 charts

Neoplasm Metastasis, Prostatic Neoplasms

NCT00685646 2015-10-16

ZAPCA

227 enrolled

Neoplasm Metastasis, Prostatic Neoplasms

NCT01062503 2015-04-27

SubDueP

Completed

48 enrolled

Neoplasm Metastasis, Neoplasms, Prostatic Neoplasms

NCT00219219 2015-04-14

Zoledronic Acid in the Prevention of Skeletal-related Events in Hormone Refractory and Hormone-sensitive Prostate Cancer Patients With Bone Metastases

Prostatic Neoplasms

NCT00151073 2015-01-22

Estramustine, Docetaxel and Zoledronate Treatment in Hormone-Refractory Adenocarcinoma of the Prostate

28 enrolled

Prostatic Neoplasms

NCT00242567 2014-05-07

Study of Zoledronic Acid for Patients With Hormone-sensitive Bone Metastases From Prostate Cancer

522 enrolled 8 charts

Prostatic Neoplasms

NCT00489905 2013-10-23

Study on Evaluation of Zoledronic Acid to Prevent Bone Loss in Men Receiving Androgen Deprivation Therapy for Prostate Cancer

24 enrolled

Prostatic Neoplasms

NCT00554918 2013-08-07

Docetaxel and Prednisolone With or Without Zoledronic Acid and/or Strontium Chloride Sr 89 in Treating Patients With Prostate Cancer Metastatic to Bone That Has Not Responded to Hormone Therapy

300 enrolled

Neoplasm Metastasis, Prostatic Neoplasms

NCT00181584 2013-07-11

Zoledronic Acid to Prevent Bone Loss During Androgen Deprivation Therapy for Prostate Cancer

60 enrolled

Bone Diseases, Metabolic, Prostatic Neoplasms

NCT00004928 2013-06-19

Calcitriol and Zoledronate in Treating Patients With Progressive Prostate Cancer

Phase 1 Completed

Prostatic Neoplasms

NCT00039104 2013-06-05

Zoledronate and BMS-275291 in Treating Patients With Prostate Cancer

50 enrolled

Prostatic Neoplasms

NCT00558272 2013-05-27

Study to Evaluate the Safety and Effects AZD0530 on Prostate and Breast Cancer Subjects With Metastatic Bone Disease

BreastGenitourinarySarcoma

139 enrolled 23 charts

Bone Diseases, Bone Neoplasms, Breast Neoplasms, Prostatic Neoplasms

NCT00005073 2013-05-01

Zoledronate Plus Standard Therapy Compared With Placebo Plus Standard Therapy to Prevent Bone Metastases in Patients With Recurrent Prostate Cancer That Has No Symptoms

544 enrolled

Prostatic Neoplasms

NCT00294437 2012-05-01

ZOMETA® (Zoledronic Acid) for Prevention of Bone Metastases

376 enrolled

Prostatic Neoplasms

NCT00172016 2012-04-30

A Study to Evaluate the Efficacy and Tolerability of Zoledronic Acid in Patients With Metastatic Prostate Cancer Who Can be Treated With a Group of Medications Known as Bisphosphonates

43 enrolled

Prostatic Neoplasms

NCT00029224 2012-02-01

Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions

BreastGenitourinaryPlasma cell

500 enrolled

Breast Neoplasms, Multiple Myeloma, Pain, Prostatic Neoplasms

NCT00237159 2011-03-23

Effect of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastasis

284 enrolled

BreastGenitourinaryThoracic

Prostatic Neoplasms

NCT00264420 2010-12-21

Safety and Efficacy Study of Concomitant Radiotherapy and Zoledronic Acid for Bone Metastases Palliation

Phase 1 Completed

4 enrolled

Breast Neoplasms, Lung Neoplasms, Prostatic Neoplasms

NCT00181558 2010-05-10

Atrasentan and Zometa for Men With Prostate Cancer Metastatic to Bone

44 enrolled

Prostatic Neoplasms

NCT00258765 2010-04-26

Adjuvant Docetaxel-Zoledronic Acid in High-risk Early Prostate Cancer Following Prostatectomy.

Phase 2 Terminated

1 enrolled

Prostatic Neoplasms

NCT00415779 2010-02-24

ZANTE

Phase 1 Completed

36 enrolled

Prostatic Neoplasms

NCT00035997 2009-11-23

Open-label Trial on the Effect of I.V. Zoledronic Acid 4 mg on Bone Density in Hormone Sensitive Prostate Cancer Patients With Bone Metastasis

261 enrolled

Prostatic Neoplasms

NCT00087659 2009-11-23

A Prostate Cancer Study in Men Undergoing Androgen Deprivation Therapy

Prostatic Neoplasms

NCT00391950 2009-11-23

Maintaining Bone Strength in Men With Prostate Cancer

300 enrolled

Prostatic Neoplasms

NCT00636740 2009-02-20

Multi-Center Phase II Study to Compare MER-101 20mg Tablets to Intravenous Zometa 4mg in Male Bisphosphonate-Naive, Hormone Refractory Prostate Cancer Patients

30 enrolled

Prostatic Neoplasms

NCT00072930 2008-01-15

MEDI-522 in the Treatment of Patients With Metastatic Androgen-Independent Prostate Cancer

150 enrolled

Prostatic Neoplasms

NCT00520052 2007-08-23

Frequency of Zoledronic Acid to Prevent Further Bone Loss in Osteoporotic Patients Requiring Androgen Deprivation Therapy for Prostate Cancer

58 enrolled